<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02352753</url>
  </required_header>
  <id_info>
    <org_study_id>20130173</org_study_id>
    <secondary_id>2014-000184-40</secondary_id>
    <nct_id>NCT02352753</nct_id>
  </id_info>
  <brief_title>Multicenter,Single-arm Study to Evaluate Efficacy, Safety, &amp; Pharmacokinetics of Denosumab in Children w/ OI</brief_title>
  <acronym>OI</acronym>
  <official_title>Prospective, Multicenter, Single-arm Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Denosumab in Children With Osteogenesis Imperfecta</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter, single-arm study in children 2 to 17 years of age with OI
      to evaluate efficacy and safety of denosumab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the effect of denosumab on lumbar spine bone mineral density(BMD) Z-score at 12
      months, as assessed by dual-energy X-ray absorptiometry (DXA), inchildren 2 to 17 years of
      age with osteogenesis imperfecta.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 24, 2015</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in lumbar spine BMD Z-score, as assessed by DXA,</measure>
    <time_frame>12 months</time_frame>
    <description>Change in lumbar spine BMD Z-score, as assessed by DXA,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in lumbar spine BMD Z-score, as assessed by DXA, at 6, 18, 24,</measure>
    <time_frame>6.18,24,36 months</time_frame>
    <description>Change from baseline in lumbar spine BMD Z-score, as assessed by DXA, at 6, 18, 24, and 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in proximal femur BMD Z-score, as assessed by DXA</measure>
    <time_frame>6, 12, 18, 24, and 36 months</time_frame>
    <description>Change in proximal femur BMD Z-score, as assessed by DXA, at 6, 12, 18, 24, and 36 months (in subjects 5 years of age and older)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new and worsening fractures (X-ray confirmed long bone and vertebral</measure>
    <time_frame>12, 24, and 36 months</time_frame>
    <description>Incidence of new and worsening fractures (X-ray confirmed long bone and vertebral fractures) from pre-treatment to post-treatment at 12, 24, and 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of improving vertebral fractures from pre-treatment to post-treatment</measure>
    <time_frame>12, 24, and 36 months</time_frame>
    <description>Incidence of improving vertebral fractures from pre-treatment to post-treatment at 12, 24, and 36 months (overall, among subjects with clinical fracture reduction, and among subjects with clinical fracture increase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of pre-treatment compared with post-treatment vertebral and nonvertebral</measure>
    <time_frame>12, 24, and 36 months</time_frame>
    <description>Incidence of pre-treatment compared with post-treatment vertebral and nonvertebral fractures at 12, 24, and 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Child Health Questionnaire (CHQ)-Parent Form (PF)-50 Physical Summary</measure>
    <time_frame>12, 24, and 36 months</time_frame>
    <description>Change in Child Health Questionnaire (CHQ)-Parent Form (PF)-50 Physical Summary score at 12, 24, and 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CHQ-PF-50 Psychological Summary score</measure>
    <time_frame>12, 24, and 36 months</time_frame>
    <description>Change in CHQ-PF-50 Psychological Summary score at 12, 24, and 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Childhood Health Assessment Questionnaire (CHAQ) Disability Index score</measure>
    <time_frame>12, 24, and 36 Months</time_frame>
    <description>Childhood Health Assessment Questionnaire (CHAQ) Disability Index score at 12, 24, and 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Wong-Baker Faces Pain Rating Scale (WBFPRS)</measure>
    <time_frame>12, 24, and 36 months</time_frame>
    <description>Change in Wong-Baker Faces Pain Rating Scale (WBFPRS) at 12, 24, and 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of denosumab</measure>
    <time_frame>1 and 10 days and 6, 12, 18, 24, 30, and</time_frame>
    <description>Serum concentration of denosumab at 1 and 10 days and 6, 12, 18, 24, 30, and 36 months in all subjects (additional serum denosumab pharmacokinetics [PK] samples to be collected at day 30 and month 3 in a PK/bone turnover markers (BTM) substudy of approximately 50 subjects).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Subject incidence of adverse events and serious adverse events</measure>
    <time_frame>36 months</time_frame>
    <description>Subject incidence of adverse events and serious adverse events</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Osteogenesis Imperfecta</condition>
  <arm_group>
    <arm_group_label>Denosumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>All subjects will receive denosumab 1 mg/kg (up to a maximum of 60 mg) given subcutaneously every 6 months for 36 months.</description>
    <arm_group_label>Denosumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Clinical diagnosis of OI defined as a clinical history consistent with type I-IV OI
        Clinical severity of OI as defined by 2 or more prevalent vertebral compression fractures;
        OR1 prevalent vertebral compression fracture and 1 or more nonvertebral fractures within
        the previous 2 years; OR 3 or more fractures within the previous 2 years.

        Exclusion Criteria:

          -  Inability or unwillingness to comply with the requirements for frequent calcium and
             phosphorus monitoring for 14 days after the first dose of denosumab (only applies to
             the first 5 subjects age 11 to17 enrolled in the study and the first 5 subjects of any
             age meeting the criteria for increased bone turnover

          -  Currently unhealed fracture or osteotomy as defined by orthopedic opinion

          -  Osteotomy within 5 months of screening

          -  Evidence of untreated oral cavities or oral infections

          -  Recent or planned invasive dental procedure

          -  Surgical tooth extraction which has not healed by screening

          -  History of an electrophoresis pattern inconsistent with type I to IV OI

          -  History of genetic testing results inconsistent with type I to IV OI

          -  Abnormalities of the following per central laboratory reference ranges at screening:
             Serum albumin corrected calcium &lt; lower limit of normal (LLN) Serum vitamin D &lt; 20
             ng/mL; re-screening for Vitamin D level &lt; 20 ng/mL will be allowed, after adequate
             supplementation

          -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT) &gt; 1.5 x upper limit
             of normal (ULN)

               -  Total bilirubin (TBL) &gt; 1.5 x ULN (subjects with Gilbert syndrome are eligible)

               -  Serum phosphorus &lt; LLN

               -  Serum alkaline phosphatase &gt; 20% above the ULN or &gt; 20% below the LLN

               -  Estimated glomerular filtration rate (eGFR) &lt; 60 mL/min/1.73 m2 (calculated bythe
                  Schwartz equation at screening) Evidence of any of the following: Current
                  hyperthyroidism (unless well-controlled on stable antithyroid therapy)

               -  Current clinical hypothyroidism (unless well-controlled on stable thyroid
                  replacement therapy)

               -  History of hyperparathyroidism

               -  Current hypoparathyroidism

               -  Current, uncontrolled hypercalcemia (albumin-corrected serum Ca &gt;10% ULN)

               -  History of osteomalacia or rickets (chart review)

               -  Other bone diseases that affect bone metabolism (eg, osteoporosis pseudoglioma
                  syndrome, idiopathic juvenile osteoporosis, osteopetrosis, hypophosphatasia)

               -  History of autoimmune disease

               -  History of rare hereditary problems of fructose intolerance

               -  Positive blood screen for human immunodeficiency virus -1 or -2 antibody

               -  Positive blood screen for hepatitis B surface antigen or hepatitis C antibody

               -  Received other osteoporosis treatment or bone active treatment with the following
                  guidelines:

               -  Prior treatment with

               -  § denosumab

               -  § fluoride or strontium for bone disease

               -  § parathyroid hormone (PTH) or PTH derivatives within 12 months prior to
                  screening

               -  § zoledronic acid within 6 months prior to screening

               -  § oral bisphosphonates or intravenous bisphosphonates other than zoledronic acid
                  if the first dose of denosumab would be before their next scheduled
                  bisphosphonate dose would have been given

               -  Administration of systemic glucocorticoids (≥ 5.0 mg prednisone equivalents/day
                  for more than 10 days) within 3 months of screening.

               -  Topical and inhaled glucocorticoids will be allowed

               -  Administration of any of the following treatment within 3 months of screening:

               -  § Growth hormone (subjects on stable dose of growth hormone for at least 3 months
                  prior to screening will be allowed)

               -  Currently receiving treatment in another investigational drug study, or less than
                  30 days since ending treatment on another investigational drugstudy(s), or
                  current or planned participation in a clinical trial that would preclude
                  compliance with study requirements Other inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pardubice</city>
        <zip>532 03</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plzen</city>
        <zip>305 99</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 4</city>
        <zip>140 59</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris Cedex 15</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Köln</city>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1094</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-274</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <zip>91-738</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <state>Cataluña</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Getafe</city>
        <state>Madrid</state>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8AE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2015</study_first_submitted>
  <study_first_submitted_qc>January 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2015</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amgen, OI, Bone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteogenesis Imperfecta</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

